FDA WARNING_LETTER - HUMAN SCIENCE FOUNDATION - January 16, 2014
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On August 18, 2014, the FDA issued a Warning Letter to Human Science Foundation, following an inspection from January 8-16, 2014, at their Gardena, CA facility. The inspection and subsequent laboratory analysis revealed that "Pro ArthMax" and "Super Arthgold," labeled as dietary supplements, contained undeclared active pharmaceutical ingredients (APIs).
"Pro ArthMax" contained Chlorzoxazone, Diclofenac, Indomethacin, Ibuprofen, Naproxen, and Nefopam. "Super Arthgold" contained Chlorzoxazone, Diclofenac, and Indomethacin. These ingredients are APIs in FDA-approved drugs (e.g., Parafon Forte DSC, Voltaren, Indocin, Motrin, Naprosyn) and, in the case of Nefopam, unapproved for use in the U.S.
The FDA determined that these products are unapproved new drugs under sections 505(a) and 201(p) of the FD&C Act, as they are not generally recognized as safe and effective and lack FDA-approved applications. They are also misbranded under sections 502 and 503(b)(1)(A) because they are prescription drugs lacking adequate directions for use and their labeling is false and misleading due to the undeclared ingredients. The undeclared APIs, particularly NSAIDs, pose
ID · 0194ad3f-9a8d-4f46-8e47-80b2e47d22c7
Full citation text and observation details available on the Dashboard.